Your browser doesn't support javascript.
loading
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Fizazi, K; Ulys, A; Sengeløv, L; Moe, M; Ladoire, S; Thiery-Vuillemin, A; Flechon, A; Guida, A; Bellmunt, J; Climent, M A; Chowdhury, S; Dumez, H; Matouskova, M; Penel, N; Liutkauskiene, S; Stachurski, L; Sternberg, C N; Baton, F; Germann, N; Daugaard, G.
Affiliation
  • Fizazi K; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: karim.fizazi@gustaveroussy.fr.
  • Ulys A; National Cancer Institute, Vilnius, Lithuania.
  • Sengeløv L; Department of Oncology, Herlev Hospital, Herlev.
  • Moe M; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
  • Ladoire S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon.
  • Thiery-Vuillemin A; INSERM, UMR1098, Besançon.
  • Flechon A; Medicine, Centre Léon Bérard, Lyon, France.
  • Guida A; Department of Oncology & Hematology, Azienda University Hospital, Modena, Italy.
  • Bellmunt J; Dana-Farber/Brigham and Women's Cancer Center, Boston, USA.
  • Climent MA; Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
  • Chowdhury S; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Dumez H; Department of General Medical Oncology, University Hospitals Leuven, Leuven; KU Leuven, Leuven, Belgium.
  • Matouskova M; Urocentrum, Prague, Czech Republic.
  • Penel N; General Oncology Department, Centre Oscar Lambret, Lille, France.
  • Liutkauskiene S; Lithuanian University of Health Sciences Hospital, Kaunas, Lithuania.
  • Stachurski L; Gabinet Urologiczny, Gdynia, Gdansk, Poland.
  • Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
  • Baton F; Ipsen Innovation, Les Ulis, France.
  • Germann N; Ipsen Innovation, Les Ulis, France.
  • Daugaard G; Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Ann Oncol ; 28(11): 2741-2746, 2017 Nov 01.
Article de En | MEDLINE | ID: mdl-29059273
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Qualité de vie / Protocoles de polychimiothérapie antinéoplasique / Tumeurs prostatiques résistantes à la castration Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Aged / Aged80 / Humans / Male / Middle aged Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Qualité de vie / Protocoles de polychimiothérapie antinéoplasique / Tumeurs prostatiques résistantes à la castration Type d'étude: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Aged / Aged80 / Humans / Male / Middle aged Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article